|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SALV-ENZA trial is the first phase II placebo-controlled double-blinded randomized study to test SRT in combination with a next generation androgen receptor antagonist in men with high-risk recurrent prostate cancer after radical prostatectomy.
|
31196032 |
2019 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support the clinical evaluation of pTVG-AR in patients with recurrent prostate cancer.Prostate 77:812-821, 2017.
|
28181678 |
2017 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
|
28055971 |
2017 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer.
|
28306720 |
2017 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reactivation of androgen receptor (AR) may drive recurrent prostate cancer in castrate patients.
|
25950519 |
2015 |
|
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An elevated tumor tissue androgen level, which reactivates androgen receptor in recurrent prostate cancer, arises from the intratumor synthesis of 5α-dihydrotestosterone through use of the precursor steroid dehydroepiandrosterone (DHEA) and is fueled by the steroidogenic enzymes 3β-hydroxysteroid dehydrogenase (3β-HSD1), aldoketoreductase (AKR1C3), and steroid 5-alpha reductase, type 1 (SRD5A1) present in cancer tissue.
|
23579488 |
2013 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Second, NKX3-1 collaborates with AR and FoxA1 to mediate genes in advanced and recurrent prostate carcinoma.
|
22083957 |
2012 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
|
22272301 |
2012 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Key new insights are that cancer stem cells play a role in PCa and that PCa cells are dependent on the AR for proliferation, even in the hormone refractory state of the disease.
|
21864277 |
2011 |
|
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This review will provide a summary of the most recent data regarding androgen-regulated target genes and modulation of androgen receptor activity, especially with regard to androgen-dependent and castration-recurrent prostate cancer.
|
20399963 |
2010 |
|
Prostate cancer recurrent
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Increased expression of the AR coregulator MAGE-11 through promoter DNA hypomethylation and cAMP provides a novel mechanism for increased AR signaling in castration-recurrent prostate cancer.
|
19372581 |
2009 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor action in hormone-dependent and recurrent prostate cancer.
|
16619264 |
2006 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cross-talk with growth factor receptors, such as epidermal growth factor receptor (EGFR) family, has been postulated as a potential mechanism to activate AR in recurrent prostate cancer.
|
15833875 |
2005 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that heregulin signaling through HER2 and HER3 increases AR transactivation and alters growth in a recurrent prostate cancer cell line.
|
15755991 |
2005 |
|
Prostate cancer recurrent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
|
15617028 |
2005 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty-three percent of the 24 recurrent prostate cancer specimens 8 (33%) showed AR amplification.
|
14532783 |
2003 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, it is unclear whether AR is fully functional in recurrent prostate cancer after androgen withdrawal.
|
12907631 |
2003 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results suggest that AR is transcriptionally active in recurrent CaP and can increase cell proliferation at the low circulating levels of androgen reported in castrated men.
|
11306464 |
2001 |
|
Prostate cancer recurrent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer.
|
10365100 |
1999 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.
|
9076469 |
1997 |